CTA101

CTA101 is an allogeneic, off-the-shelf universal CAR-T cell therapy developed using CRISPR-Cas9 gene editing technology. It is designed to target both B-lymphocyte antigen CD19 and B-cell receptor CD22 on the surface of B-cell malignancies. The product is manufactured from healthy donor-derived T cells in which the endogenous T cell receptor (TCR) and CD52 are disrupted using CRISPR-Cas9. This engineering allows for reduced risk of graft-versus-host disease and resistance to anti-CD52 antibody therapies used during lymphodepletion. Upon administration, CTA101 specifically binds to and lyses tumor cells expressing CD19 or CD22, making it a promising candidate for relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL). Clinical trials are ongoing in China with sponsorship from academic institutions such as Zhejiang University[1][3][4][5][6].

Other names

CD19-targeted CAR-T cellsCD-19-targeted CAR-T cellsCD 19-targeted CAR-T cellsCD19 UCAR-TCD-19 UCAR-TCD 19 UCAR-TBioheng CD19 CAR-T